Tissue repair is not a single process — it's an orchestrated sequence of overlapping biological events that unfolds over days to weeks after injury. Understanding this sequence is essential for understanding where each recovery peptide intervenes.

Phase 1: Inflammation (hours to days). Immediately after injury, the body mounts an inflammatory response. Blood vessels dilate, immune cells (neutrophils, macrophages) infiltrate the area, and inflammatory mediators (TNF-α, IL-1β, IL-6) are released. This phase clears debris and pathogens but can become destructive if excessive or prolonged.

Phase 2: Proliferation (days to weeks). Fibroblasts migrate to the wound site and begin producing new extracellular matrix (collagen, elastin, proteoglycans). Endothelial cells form new blood vessels (angiogenesis) to supply the growing tissue. Epithelial cells migrate across the wound surface (re-epithelialization).

Phase 3: Remodeling (weeks to months). The initial repair matrix is reorganized and strengthened. Collagen is cross-linked by lysyl oxidase. The tissue gradually approaches (but rarely achieves) its pre-injury strength and organization.

Each OSYRIS recovery compound targets a different step in this sequence.

BPC-157 is the most extensively studied compound in the Recovery category. Its mechanism centers on amplifying the body's repair signals — upregulating growth factors (EGF, VEGF, FGF) that recruit repair cells, stimulate blood vessel formation, and drive collagen synthesis. The FAK-paxillin pathway activation promotes organized cell adhesion and directional migration.

Unique strengths: Broadest tissue type coverage (tendon, muscle, skin, GI, cornea, nerve), reported oral activity in animal models, extensive GI research portfolio, dual tissue repair + NO system modulation.

Evidence context: Over 100 PubMed publications, primarily from the University of Zagreb group. Independent replication emerging but limited. No human clinical trials.

Best for protocols studying: Growth factor-mediated repair, GI tissue biology, multi-tissue repair models, oral delivery research.

→ Read the full BPC-157 research overview → View BPC-157 product page

TB500 provides the structural machinery that repair cells need to respond to growth factor signals. Its mechanism — actin polymerization and cytoskeletal reorganization — gives cells the physical capacity to migrate to injury sites. Where BPC-157 sends the "come here" signal, TB500 gives cells better legs to get there.

Unique strengths: Cardiac research (Nature publication on cardiomyocyte survival), internationally distributed evidence base (multiple independent research groups), anti-inflammatory properties through NF-κB modulation, established corneal wound healing data.

Evidence context: Extensive Thymosin Beta-4 literature from multiple international laboratories. The full protein (43 amino acids) has more published data than the TB500 fragment specifically.

Best for protocols studying: Cell migration dynamics, cardiac repair biology, actin cytoskeleton research, corneal wound models.

→ Read the full TB500 research overview → View TB500 product page

The BPC/TB500 Blend and the multi-compound stacks (GLOW, KLOW) exist because tissue repair involves multiple simultaneous processes. A single compound targeting one mechanism addresses one bottleneck but leaves others unaddressed.

BPC/TB500 Blend targets the two most fundamental repair processes: signaling (BPC-157) and cell migration (TB500). The hypothesis: activating both produces effects neither achieves alone. Published evidence for the specific combination is limited — the rationale is based on the non-overlapping mechanisms documented independently for each compound.

GLOW adds GHK-Cu to the BPC-157 + TB500 combination, introducing copper-dependent collagen cross-linking and gene expression modulation (4,000+ genes affected in fibroblast studies). This creates a three-mechanism approach: signaling + migration + gene expression.

KLOW adds KPV to the GLOW formula, introducing direct NF-κB inhibition. This addresses the inflammation phase of repair — the critical first step that, when excessive, prevents effective tissue regeneration. KLOW is the only stack that targets both the inflammatory and proliferative phases.

Single-mechanism studies: Use BPC-157 or TB500 individually to study one pathway in isolation with controlled variables.

Dual-mechanism studies: Use the BPC/TB500 Blend for protocols investigating whether simultaneous signaling and migration activation produces additive or synergistic effects.

Multi-mechanism studies: Use GLOW (aesthetics focus: collagen/skin) or KLOW (immune focus: inflammation + repair) for protocols studying comprehensive tissue remodeling.

Comparative studies: Use all available compounds side by side to isolate each mechanism's contribution to repair outcomes.

Recovery compounds appear across the OSYRIS catalog:

• GLOW is cross-listed to Aesthetics (skin/collagen focus)
• KLOW is cross-listed to Immune (NF-κB/inflammation focus) and Aesthetics
• BPC-157 has GI research relevant to Metabolic models
• GHK-Cu (in GLOW/KLOW) has gene expression data relevant to Longevity models

These cross-listings reflect the biological reality that tissue repair intersects with multiple research domains.